CD19 CAR T-Cell Therapy for R/R Non-Hodgkin Lymphoma and Acute Lymphoblastic Leukemia

Inclusion criteria: * B-cell acute lymphoblastic leukemia: refractory to two cycles of chemotherapy, relapsed after chemotherapy, or hematopoietic stem cell transplantation. * B-cell non-Hodgkin lymphoma: refractory to two lines of chemotherapy, relapsed after chemotherapy, or hematopoietic stem cell transplantation. * Age: From 1 to 60 years old (both males and females) * Adequate organ functions: * Serum creatinine ≤ 1.5 x ULN or eGFR ≥ 60 mL/min/1.73 m2 * ALT and AST ≤ 5 x ULN; Bilirubin ≤ 2.0 mg/dl * No chronic lung diseases, such as obstructive pulmonary disease or bronchial asthma, required continuous medications without respiratory failure (SpO2 oxygen saturation \> 92% at room temperature). * No arrhythmia, no intracardiac thrombus or vascular wall, no heart failure, LVEF ≥ 45% * Blood test: * Absolute neutrophil count (ANC) ≥ 1,000/mm3 (1 G/l) without filgrastim * Absolute lymphocyte count ≥ 100/mm3 (0.1 G/l) * Absolute platelet count ≥ 75,000/mm3 (75 G/l) * Hemoglobin ≥ 8.0 g/dl * Positive for CD19 measured by immunohistochemistry or flow cytometry. * Agree to participate in the study * Agree to use safe methods of contraception for female patients. Exclusion criteria: * Involved central nervous system invasion at the time of screening. * Medical history of veno-occlusive disease (VOD). * Required acute treatment due to tumors such as intestinal obstructions, vascular compression, or respiratory failure. * Having active hemolytic anemia. * Diagnosed with primary immunodeficiency. * Medical history of autoimmune neurological diseases or neuromyelitis. * Receiving immunosuppressive medication, except for ≤ 30 mg prednisolone or equivalent at the time of CAR-T-cell transfusion. * Having acute, progressive, or chronic graft-versus-host disease (GvHD). * Having active infectious diseases determined by clinical, imaging, or other laboratory tests (blood culture, PCR, etc.) * Patients who are critically ill or at risk of premature death characterized by: * Acute liver failure requiring dialysis * Heart failure requiring vasopressors * Systemic infection unresponsive to antibiotics * ECOG performance status ≥ 3 points at the time of screening * Having other severe concomitant diseases (e.g., uncontrolled arterial hypertension, heart failure NYHA III-IV). * Unstable angina within 3 months prior to screening. * Any previous or concurrent malignancy was not B-cell lymphoma or B-ALL. * Medical history of clinically relevant central nervous system disease, such as epilepsy, convulsions, paralysis, aphasia, uncontrolled cerebrovascular disease, traumatic brain injury, and Parkinson's disease. * Intolerance to excipients from cellular products. * Pregnant women or those who expect to be pregnant or reastfeeding. * Other diseases or other conditions and circumstances that, according to the investigator's assessment, make it difficult to ensure compliance with study treatment. * Participation in another clinical trial at the time of screening